Impact Therapeutics, Inc.

This study tested a new drug called IMP4297 in 93 adults with advanced ovarian cancer that has a BRCA1 or BRCA2 gene mutation and has stopped responding to at least two prior chemotherapies. The goal was to see if the drug could shrink tumors and how safe it was. The drug is take…

This study tested whether a 10 mg and a 20 mg capsule of an experimental drug called IMP4297 are processed the same way in the body. It involved 36 healthy Chinese adults who took a single dose of each strength on separate days. The goal was to gather information on how the drug …

This study looked at how a drug called IMP4297, being developed for solid tumors, is absorbed, broken down, and removed from the body. Six healthy Chinese men took a single dose, and researchers measured the drug in their blood, urine, and stool. The goal was to understand the dr…

This study tested whether a 10 mg and a 20 mg capsule of the experimental drug IMP4297 are processed similarly by the body. It involved 28 healthy Chinese adults who took a single dose of each strength on separate days. The goal was to check bioequivalence, not to treat any disea…